Business Context and Reporting Period
This Form 8-K Current Report was filed by Vistagen Therapeutics, Inc. on February 6, 2026, regarding an event dated February 3, 2026. The Company is a Nevada corporation with its principal executive offices in South San Francisco, California, and its Common Stock (VTGN) is listed on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
On February 3, 2026, the Company received a Notice from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC indicating non-compliance with Nasdaq Listing Rule 5550(a)(2). The Company failed to maintain a minimum closing bid price of $1.00 per share for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's Common Stock.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has a 180-calendar day period from February 3, 2026, to August 3, 2026, to regain compliance. The closing bid price must be at least $1.00 per share for 10 consecutive business days within this window.
- Extension Possibility: If compliance is not achieved by August 6, 2026, Nasdaq may grant a second 180-day period. Qualification for this extension requires meeting the market value of publicly held shares and all other initial listing standards, excluding the minimum bid price requirement.
- Delisting Risk: If the Company fails to regain compliance within the allotted periods, including any extensions, Nasdaq will provide notice that the Common Stock will be subject to delisting.
- Uncertainty: Management states there can be no assurance that the Company will regain compliance or maintain other listing requirements.
Investor Verification Checklist
- Verify the current closing bid price of VTGN to assess proximity to the $1.00 threshold.
- Monitor the Company's ability to achieve 10 consecutive days of compliance before August 3, 2026.
- Review the Company's market value of publicly held shares to determine eligibility for a potential second compliance period.
- Check for any subsequent filings regarding stock splits or other corporate actions intended to address the bid price deficiency.